Literature DB >> 27349476

Microenvironmental InterFereNce of metabolism regulates chemosensitivity.

Leila Akkari1,2, Johanna A Joyce1,2.   

Abstract

The tumor microenvironment is recognized as a critical regulator of cancer progression, and multiple roles are also emerging for the microenvironment in modulating response to therapeutic intervention. A recent study by Wang and colleagues identified IFN-γ as a central effector of CD8 T cell-mediated regulation of glutathione and cysteine metabolism in fibroblasts, which consequently abrogates stromal-induced resistance through modulation of cisplatin intracellular content in ovarian cancer cells.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27349476      PMCID： PMC4973332          DOI： 10.1038/cr.2016.82

Source DB:  PubMed          Journal:  Cell Res        ISSN： 1001-0602            Impact factor:   25.617


  10 in total

1.  Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

Authors:  Matthew Kraman; Paul J Bambrough; James N Arnold; Edward W Roberts; Lukasz Magiera; James O Jones; Aarthi Gopinathan; David A Tuveson; Douglas T Fearon
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

2.  Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

Authors:  Timothy R Wilson; Jane Fridlyand; Yibing Yan; Elicia Penuel; Luciana Burton; Emily Chan; Jing Peng; Eva Lin; Yulei Wang; Jeff Sosman; Antoni Ribas; Jiang Li; John Moffat; Daniel P Sutherlin; Hartmut Koeppen; Mark Merchant; Richard Neve; Jeff Settleman
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

Review 3.  Microenvironmental regulation of therapeutic response in cancer.

Authors:  Florian Klemm; Johanna A Joyce
Journal:  Trends Cell Biol       Date:  2014-12-22       Impact factor: 20.808

4.  Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma.

Authors:  Alexandre Labiche; Natacha Heutte; Paulette Herlin; Jacques Chasle; Pascal Gauduchon; Nicolas Elie
Journal:  Int J Gynecol Cancer       Date:  2010-01       Impact factor: 3.437

5.  Effector T Cells Abrogate Stroma-Mediated Chemoresistance in Ovarian Cancer.

Authors:  Weimin Wang; Ilona Kryczek; Lubomír Dostál; Heng Lin; Lijun Tan; Lili Zhao; Fujia Lu; Shuang Wei; Tomasz Maj; Dongjun Peng; Gong He; Linda Vatan; Wojciech Szeliga; Rork Kuick; Jan Kotarski; Rafał Tarkowski; Yali Dou; Ramandeep Rattan; Adnan Munkarah; J Rebecca Liu; Weiping Zou
Journal:  Cell       Date:  2016-04-28       Impact factor: 41.582

6.  Mitochondria "fuel" breast cancer metabolism: fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells.

Authors:  Federica Sotgia; Diana Whitaker-Menezes; Ubaldo E Martinez-Outschoorn; Ahmed F Salem; Aristotelis Tsirigos; Rebecca Lamb; Sharon Sneddon; James Hulit; Anthony Howell; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-11-21       Impact factor: 4.534

7.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

8.  Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.

Authors:  Kenneth P Olive; Michael A Jacobetz; Christian J Davidson; Aarthi Gopinathan; Dominick McIntyre; Davina Honess; Basetti Madhu; Mae A Goldgraben; Meredith E Caldwell; David Allard; Kristopher K Frese; Gina Denicola; Christine Feig; Chelsea Combs; Stephen P Winter; Heather Ireland-Zecchini; Stefanie Reichelt; William J Howat; Alex Chang; Mousumi Dhara; Lifu Wang; Felix Rückert; Robert Grützmann; Christian Pilarsky; Kamel Izeradjene; Sunil R Hingorani; Pearl Huang; Susan E Davies; William Plunkett; Merrill Egorin; Ralph H Hruban; Nigel Whitebread; Karen McGovern; Julian Adams; Christine Iacobuzio-Donahue; John Griffiths; David A Tuveson
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

9.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Authors:  Ravid Straussman; Teppei Morikawa; Kevin Shee; Michal Barzily-Rokni; Zhi Rong Qian; Jinyan Du; Ashli Davis; Margaret M Mongare; Joshua Gould; Dennie T Frederick; Zachary A Cooper; Paul B Chapman; David B Solit; Antoni Ribas; Roger S Lo; Keith T Flaherty; Shuji Ogino; Jennifer A Wargo; Todd R Golub
Journal:  Nature       Date:  2012-07-26       Impact factor: 49.962

10.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.

Authors:  Christine Feig; James O Jones; Matthew Kraman; Richard J B Wells; Andrew Deonarine; Derek S Chan; Claire M Connell; Edward W Roberts; Qi Zhao; Otavia L Caballero; Sarah A Teichmann; Tobias Janowitz; Duncan I Jodrell; David A Tuveson; Douglas T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205
  10 in total
  4 in total

Review 1.  Consider the chemokines: a review of the interplay between chemokines and T cell subset function.

Authors:  Marianne Strazza; Adam Mor
Journal:  Discov Med       Date:  2017-08       Impact factor: 2.970

2.  Redox-responsive cisplatin nanogels for anticancer drug delivery.

Authors:  Weiqi Zhang; Ching-Hsuan Tung
Journal:  Chem Commun (Camb)       Date:  2018-07-24       Impact factor: 6.222

3.  The senescence-associated secretory phenotype is potentiated by feedforward regulatory mechanisms involving Zscan4 and TAK1.

Authors:  Boyi Zhang; Da Fu; Qixia Xu; Xianling Cong; Chunyan Wu; Xiaoming Zhong; Yushui Ma; Zhongwei Lv; Fei Chen; Liu Han; Min Qian; Y Eugene Chin; Eric W-F Lam; Paul Chiao; Yu Sun
Journal:  Nat Commun       Date:  2018-04-30       Impact factor: 14.919

Review 4.  The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents.

Authors:  Jiabei Zhou; Yu Kang; Lu Chen; Hua Wang; Junqing Liu; Su Zeng; Lushan Yu
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.